Oncology

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The CAR T-cell therapy from Janssen and Legend Biotech is the second to receive approval with an indication for treatment of multiple myeloma.

The phase 1b KEYNOTE-B79 trial is investigating the allogeneic cell therapy in participants with metastatic colorectal cancer.

Review top news and interview highlights from the week ending February 25, 2022.

An interim safety review of 81 patients informed the DSMB's recommendation for the trial to continue.

CT103A is co-developed by IASO Biotherapeutics and Innovent Biologics.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The pause follows a fatal serious adverse event in the first patient treated in the highest dose cohort.

The trial, sponsored by Mustang Bio, will continue to enroll patients and doses will be escalated to 300 million cells.

The new application is based on data from the phase 3 TRANSFORM trial.

Review top news and interview highlights from the week ending February 18, 2022.

Interim data from the SPOTLIGHT study were presented at the ASCO GU Symposium.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Only 1 patient has been dosed in the trial so far, which initiated in October 2021.

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed CAR T-cell therapies and safety signals of cilta-cel.

This designation follows a fast track designation and IND application approval for the agent.

The director of research and development at AVROBIO discussed the analytical pipeline the company has developed for molecular follow-up of cell therapies.

The translational immunologist and research professor at Perelman School of Medicine, University of Pennsylvania, discussed persistence of CD4+ CAR T-cells in CLL.

Review top news and interview highlights from the week ending February 11, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.

Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed the company’s collaboration with 2seventy bio to develop TCR T-cell therapies.

Review top news and interview highlights from the week ending February 4, 2022.

Carl June, MD, discussed the longest-term follow-up data on CAR T-cell therapy so far.

Kimmtrak is now the first approved therapy for unresectable or metastatic uveal melanoma.